Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence

Launched by UNIVERSITY OF WASHINGTON · Jun 11, 2021

Keywords

ClinConnect Summary

The SISTER study is a clinical trial that aims to understand how different types of social support can help Black patients who are undergoing treatment for endometrial cancer. The study is looking at three different ways to provide support: group support, one-on-one peer support, and enhanced usual care. The main goal is to see if these support options help patients complete their cancer treatment, while also looking at how these interventions might reduce feelings of social isolation.

To participate in this trial, you need to be a Black woman aged 18 or older who has been diagnosed with high-risk endometrial cancer. This includes various stages and types of endometrial cancer, and you must have a plan to start treatment like chemotherapy, radiation, or immunotherapy. If you choose to take part, you will receive one of the support options mentioned above during your treatment. It's important to note that the study is currently recruiting participants, so if you meet the eligibility requirements, you could be part of this meaningful research that aims to improve care and support for Black women facing this diagnosis.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult 18 years of age or older; and
• • 2. Self-identify as Black/African American
• 3. Presenting with high-risk EC established by anatomic pathology as tumor stage and grade classification by the following:
• • 1. Pathology documentation from any hospital/clinic/medical center, and
• • 2. FIGO Stage 1A with Grade 2, Grade 3, or Grade 4 of any histology type or
• • 3. FIGO Stage 1A with non-endometrioid (carcinosarcoma, serous, clear cell, undifferentiated or mixed) histology
• • 4. FIGO Stage 1B, 2, 3, or 4 of any grade or histology
• • 5. Recurrent endometrial cancer of any stage or grade
• • 4. Documented provider recommendation and patient plan to initiate adjuvant therapy with chemotherapy, radiation, and/or immunotherapy.
• Exclusion Criteria:
• Participants must not have any of the following exclusion criteria:
• • 1. Newly diagnosis of FIGO Stage IA Grade 1 endometrioid adenocarcinoma
• • 2. Previous history of other cancer diagnosis requiring chemotherapy, radiation therapy, or immunotherapy within the past 12 months;
• • 3. Incarcerated in a detention facility or in police custody (patients wearing a monitoring device can be enrolled) at baseline/screening;
• • 4. Contraindication to all non-surgical therapy available for endometrial cancer (i.e., chemotherapy, radiation, and immunotherapy contraindicated);
• • 5. Enrollment into hospice prior to randomization
• • 6. Unable to provide written informed consent in English;
• • 7. Unable to be contacted for research surveys;
• • 8. Recent hospitalization for psychiatric illness in the past 6 months